Alzamend Neuro, Inc.
Alzamend Neuro, Inc. (ALZN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ALZN · as of Sep 30, 2025
Ownership Breakdown
11
Institutional Holders
▲ 4 vs Q2
$351,338
Total Inst. Value
▲ $344,983 vs Q2
3.14M
Shares Outstanding
freeFloat 96.76%
147,622
13F Shares Held
▲ 145,438 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ALZN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DRW SECURITIES, LLC pharmaceutical preparations | 91.2K | 2.70% | 2.70% | $217.16M | Nov 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 21.6K | 63.95% | 63.95% | $51.46M | Nov 7, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 20.6K | 60.86% | 60.86% | $48.97M | Nov 12, 2025 | NEW |
CLEARSTEAD ADVISORS, LLC pharmaceutical preparations | 10.0K | 29.58% | 29.58% | $23.80M | Nov 10, 2025 | NEW |
UBS GROUP AG pharmaceutical preparations | 2.1K | 6.14% | 6.14% | $4.94M | Nov 13, 2025 | ▲ 1.2K |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 1.6K | 4.75% | 4.75% | $3.82M | Nov 14, 2025 | ▲ 809 |
BLACKROCK, INC. pharmaceutical preparations | 437 | 1.29% | 1.29% | $1.04M | Nov 12, 2025 | ▼ 4 |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 37 | 0.11% | 0.11% | $88,000 | Feb 3, 2026 | ▲ 18 |
SBI SECURITIES CO., LTD. pharmaceutical preparations | 22 | 0.07% | 0.07% | $52,000 | Nov 5, 2025 | — held |
HARBOR INVESTMENT ADVISORY, LLC pharmaceutical preparations | 1 | 0.00% | 0.00% | $2,000 | Oct 27, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
3
Increased
+2.0K shares5
New Positions
first time holders1
Decreased
−4 shares1
Sold Out
fully exitedNet shares change (top 50)
+2.0K
+2.0K / −4
Net new holders
+6
5 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ALZN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
AULT MILTON C III director | Apr 14, 2026 | Purchase | 108,388 | $1.00 | $108.9K | 116.6K | Form 4 ↗ |
AULT MILTON C III director | Dec 23, 2025 | Sale | 1,851 | $2.07 | $3.8K | 0 | Form 4 ↗ |
Horne William B. director | Dec 19, 2025 | Sale | 3,333 | $2.12 | $7.1K | 0 | Form 4 ↗ |
McGrath Lynne Fahey director | Oct 23, 2025 | Sale | 30 | $2.29 | $68.7 | 25 | Form 4 ↗ |
AULT MILTON C III director | Oct 8, 2025 | C-Conversion | 61,743 | $2.32 | $143.2K | 130.6K | Form 4 ↗ |
AULT MILTON C III director | Oct 8, 2025 | Sale | 101,394 | $2.44 | $247.2K | 28.7K | Form 4 ↗ |
AULT MILTON C III director | Oct 9, 2025 | Sale | 20,397 | $2.32 | $47.4K | 8.3K | Form 4 ↗ |
AULT MILTON C III director | Oct 8, 2025 | C-Conversion | 143.245 | $2.32 | $332.328 | 0 | Form 4 ↗ |
AULT MILTON C III director | Oct 7, 2025 | C-Conversion | 100,000 | $2.32 | $232.0K | 126.2K | Form 4 ↗ |
AULT MILTON C III director | Oct 3, 2025 | C-Conversion | 100,000 | $2.32 | $232.0K | 108.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Alzamend Neuro, Inc. (ALZN) is primarily owned by institutional investors, who hold approximately 4.7% of total shares outstanding. Company insiders own approximately 3.24%, while retail and public investors account for the remaining 92.06%.
The largest institutional shareholder of Alzamend Neuro, Inc. is DRW SECURITIES, LLC, holding approximately 91,245 shares — equal to 2.70% of outstanding shares — as of September 30, 2025.
A total of 11 institutional investors currently hold ALZN stock, with a combined institutional value of approximately $351,338 as of the most recent 13F filing period.
Frequently asked questions
ALZN ownershipAlzamend Neuro, Inc. (ALZN) is primarily owned by institutional investors, who hold approximately 4.7% of shares. The largest shareholder is DRW SECURITIES, LLC with a 2.70% stake. Company insiders hold 3.24%. Data sourced from SEC Form 13F as of September 30, 2025.